Table 3.

Multivariable logistic regression for the adjusted odds of adjuvant endocrine therapy initiation among women diagnosed with breast cancer, 2007–2009 (n=14,902).

		AORa (95% confidence intervals) of AET initiation
		AJCC Tumor stage I–III
	Total cohort	ER+ or PR+	ER−/PR−	ER/PR unknown
Initiation of any AET
Race/Ethnicity
Non-Hispanic white	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Non-Hispanic Black	0.76 (0.66–0.88)	0.84 (0.70–1.00)	1.08 (0.57–2.04)	0.96 (0.53–1.73)
Hispanic	1.16 (1.00–1.36)	1.20 (0.99–1.46)	1.32 (0.64–2.71)	1.47 (0.78–2.77)
Asian	1.13 (0.95–1.34)	1.25 (1.01–1.54)	1.15 (0.46–2.84)	0.69 (0.33–1.47)
Age (years)
65–69	1	1	1	1
70–74	0.95 (0.86–1.06)	1.00 (0.88–1.14)	0.96 (0.57–1.63)	0.81 (0.49–1.32)
75–79	0.73 (0.66–0.81)	0.69 (0.61–0.79)	0.86 (0.48–1.53)	0.90 (0.54–1.49)
≥80	0.50 (0.45–0.56)	0.47 (0.41–0.53)	0.57 (0.31–1.06)	0.65 (0.40–1.04)
SES (% living below FPL)
1st tertile (<5.4)	1	1	1	1
2nd tertile (5.4–11.8)	1.06 (0.96–1.16)	1.02 (0.92–1.13)	1.67 (0.96–2.89)	1.13 (0.69–1.84)
3rd tertile (>11.8)	1.16 (1.05–1.28)	1.17 (1.04–1.32)	1.78 (1.00–3.15)	1.16 (0.70–1.92)
Comorbidity scores
0	1	1	1	1
1	0.95 (0.87–1.03)	0.95 (0.86–1.05)	0.75 (0.45–1.23)	0.67 (0.46–0.99)
2	0.86 (0.76–0.97)	0.81 (0.71–0.94)	1.00 (0.52–1.94)	0.74 (0.44–1.23)
3+	0.83 (0.73–0.95)	0.82 (0.70–0.96)	1.10 (0.57–2.13)	0.79 (0.46–1.37)
Initiation of tamoxifen
Race/Ethnicity
Non-Hispanic White	1	1	1	1
Non-Hispanic Black	0.70 (0.55–0.89)	0.70 (0.54–0.90)	1.05 (0.36–3.01)	1.05 (0.43–2.57)
Hispanic	0.80 (0.62–1.02)	0.78 (0.60–1.01)	1.32 (0.41–4.22)	0.68 (0.24–1.95)
Asian	0.87 (0.67–1.13)	0.84 (0.63–1.10)	1.31 (0.29–6.01)	0.90 (0.28–2.94)
Age (years)
65–69	1	1	1	1
70–74	1.05 (0.91–1.22)	1.07 (0.63–1.10)	0.64 (0.26–1.56)	1.81 (0.84–3.90)
75–79	1.03 (0.88–1.20)	1.07 (0.91–1.25)	0.64 (0.25–1.67)	0.92 (0.40–2.15)
≥80	1.09 (0.94–1.27)	1.13 (0.96–1.32)	0.64 (0.25–1.65)	1.37 (0.64–2.92)
SES (% living below FPL)
1st tertile (<5.4)	1	1	1	1
2nd tertile (5.4–11.8)	1.12 (0.98–1.28)	1.10 (0.96–1.27)	2.19 (0.85–5.64)	0.69 (0.92–1.61)
3rd tertile (>11.8)	1.30 (1.12–1.50)	1.27 (1.09–1.48)	2.00 (0.75–5.37)	1.20 (0.53–2.75)
Comorbidity scores
0	1	1	1	1
1	0.90 (0.80–1.02)	0.93 (0.82–1.05)	0.56 (0.24–1.32)	0.65 (0.35–1.21)
2	0.81 (0.68–0.98)	0.81 (0.67–0.98)	0.91 (0.31–2.71)	0.55 (0.25–1.24)
3+	0.79 (0.64–0.97)	0.81 (0.65–1.01)	1.14 (0.40–3.22)	0.28 (0.09–0.86)
Initiate aromatase inhibitors
Race/Ethnicity
Non-Hispanic white	1	1	1	1
Non-Hispanic Black	0.89 (0.78–1.02)	1.02 (0.87–1.21)	1.15 (0.52–2.51)	0.93 (0.52–1.68)
Hispanic	1.25 (1.08–1.45)	1.30 (1.09–1.55)	1.22 (0.49–3.05)	1.63 (0.88–3.03)
Asian	1.18 (1.00–1.39)	1.30 (1.08–1.57)	1.03 (0.34–3.17)	0.69 (0.31–1.52)
Age (years)
65–69	1	1	1	1
70–74	0.94 (0.85–1.03)	0.97 (0.86–1.08)	1.18 (0.61–2.30)	0.64 (0.40–1.04)
75–79	0.75 (0.68–0.83)	0.73 (0.65–0.82)	1.03 (0.49–2.14)	0.93 (0.57–1.52)
≥80	0.51 (0.46–0.56)	0.50 (0.45–0.56)	0.56 (0.25–1.26)	0.56 (0.35–0.90)
SES (% living below FPL)
1st tertile (<5.4)	1	1	1	1
2nd tertile (5.4–11.8)	1.00 (0.92–1.09)	0.96 (0.88–1.06)	1.46 (0.74–2.88)	1.28 (0.78–2.09)
3rd tertile (>11.8)	1.02 (0.93-1.13)	1.01 (0.92–1.13)	1.68 (0.83–3.93)	1.07 (0.64–1.76)
Comorbidity scores
0	1	1	1	1
1	0.99 (0.92-1.08)	1.00 (0.91–1.09)	0.88 (0.48–1.63)	0.82 (0.55–1.21)
2	0.95 (0.85–1.07)	0.93 (0.82–1.06)	1.11 (0.49–2.51)	0.97 (0.58–1.61)
3+	0.93 (0.82–1.06)	0.99 (0.90–1.08)	1.06 (0.47–2.42)	1.25 (0.72–2.18)

AOR, adjusted odds ratio; AET, adjuvant endocrine therapy; ER, estrogen receptor; PR, progesterone receptor.

^aAOR controlled for marital status, metropolitan area, tumor size, node status, tumor grade, tumor stage, surgical treatment, and chemotherapy and radiation treatment.